comparemela.com
Home
Live Updates
Castle Biosciences Reports First Quarter 2023 Results : comparemela.com
Castle Biosciences Reports First Quarter 2023 Results
Q1 2023 revenue increased 57% over Q1 2022 to $42 million
Q1 2023 total test reports increased 73% over Q1 2022
Reaffirming full-year 2023 revenue is expected to be between $170-180... | May 3, 2023
Related Keywords
Houston ,
Texas ,
United States ,
American ,
Frank Stokes ,
Derek Maetzold ,
Castle Biosciences ,
Castle Decisiondx ,
Castle Biosciences Inc ,
Linkedin ,
See The Company ,
American Joint Committee On Cancer ,
Securities Exchange ,
National Society For Cutaneous Medicine ,
Twitter ,
Instagram ,
Facebook ,
Nasdaq ,
Archives Of Dermatological Research ,
Quarter Ended March ,
Cypher Barrett ,
Cash Equivalents ,
Marketable Investment ,
Recent Accomplishments ,
Dermatological Research ,
National Society ,
Cutaneous Medicine ,
American Joint Committee ,
Workplaces United States ,
Top Workplaces United States ,
Investor Relations ,
Adjusted Revenues ,
Adjusted Gross Margin ,
Gross Margin ,
Adjusted Gross ,
Mypath Melanoma ,
Securities Act ,
Securities Exchange Act ,
Quarterly Report ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
1 ,
023 ,
Revenue ,
Ncreased ,
Dover ,
022 ,
O ,
Total ,
Pest ,
Reports ,
Us ,
Xpected ,
The ,
Etween Cstl Us14843c1053 ,
comparemela.com © 2020. All Rights Reserved.